HW
Harlan Waksal
Executive Chair

Harlan Waksal insider trades: Lyra Therapeutics (LYRA) stock purchases

Executive Chair, Lyra Therapeutics Last trade Nov 10, 2023 50 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
10
Open-market trades
since 2009
5
Companies
last trade 2023

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Harlan reports to the SEC

Open-market buys and sales

10 trades reported on SEC Form 4, newest first

DateStockTypeValue
Nov 10, 2023LYRA↑ Buy$74K
Apr 12, 2022LYRA↑ Buy$1000K
Mar 13, 2020KDMN↑ Buy$47K
Mar 11, 2020KDMN↑ Buy$50K
Aug 10, 2017KDMN↑ Buy$11K
Aug 8, 2017KDMN↑ Buy$9K
Nov 16, 2016KDMN↑ Buy$13K
Nov 14, 2016KDMN↑ Buy$14K
Jan 6, 2012SNT↑ Buy$250K
Jul 29, 2009SNT↑ Buy$14K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other LYRA insiders

Open-market trades in the last 12 months

About Harlan Waksal's insider trades

Harlan Waksal is Executive Chair at Lyra Therapeutics (LYRA). Since Jul 29, 2009, Harlan has reported 10 open-market purchases worth $1.5M and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (37 filings), conversions (2 filings), other transactions (2 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every LYRA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.